Professor Ingunn Holen

Clinical Medicine, School of Medicine and Population Health

Professor of Bone Oncology

Prof Ingunn Holen
Profile picture of Prof Ingunn Holen
i.holen@sheffield.ac.uk
+44 114 215 9011

Full contact details

Professor Ingunn Holen
Clinical Medicine, School of Medicine and Population Health
Room GU24
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Profile

For enquiries please contact - ClinMed-Operational@sheffield.ac.uk

I studied Biology and Biochemistry at the University of Oslo, Norway, and was awarded my PhD for work on the role of autophagy in cancer in 1995. I then joined the University of Sheffield as a post-doctoral research associate working on the mechanism of action of bisphosphonates. Establishing a lab research program in breast cancer bone metastasis, I gained a lectureship in 2001 and was appointed as Professor of Bone Oncology in 2014.

Research interests

The research in my team is focussed on tumour cell dissemination in bone, and how this is influenced by the microenvironment in breast and prostate cancer. In particular we use cutting edge technology to study the early stages of bone metastasis and how single cancer cells may remain dormant or start to proliferate when encountering different environments.

We work to elucidate the molecular mechanisms involved in tumour cell-bone cell interactions, and how these can be targeted by anti-cancer therapies, including CDK4/6 inhibitors. We also investigate the role of the microenvironment in driving progression of bone metastases and collaborate with colleagues in the Dept of Physics and Astronomy to elucidate the biomechanical properties of the bone metastatic niche.

I have several collaborative projects both with other researchers in the medical school, nationally and internationally. I work closely with the clinical staff on translational research projects, transferring the results from our laboratory projects into clinical feasibility studies. Together with colleagues in Leeds, Glasgow and London I have established a national in vivo tissue bank for breast cancer research funded by an “Infrastructure for Impact” grant awarded by the NC3Rs. This initiative is entitled SEARCHBreast and allows researchers to connect with partners who are wiling to share archived material on a collaborative basis thereby not having to carry out in vivo studies. Work in my team has been funded by local, regional and national charities, industry, the EU, MRC, CRUK, BCN, YCR and NC3Rs. In 2018, I and my colleague Dr Penelope Ottwell was awarded the “Julie Philipps PhD Studentship” from the charity Second Hope to support our work on the biology of secondary breast cancer. Our work on the mechanisms of tumour cell dormancy is supported by Weston Park Cancer Charity and Against Breast Cancer.

Ingunn Holden and Penelope Ottwell holding a cheque for £100,000 awarded from Second Hope
Publications

Show: Featured publications All publications

Journal articles

Conference proceedings papers

All publications

Journal articles

Chapters

Conference proceedings papers

  • Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) Abstract P2-18-08: Inclusion of adjuvant bone-modifying agents for early breast cancer into standard clinical practice: Challenges and lessons learnt from an international collaboration. Poster Session Abstracts RIS download Bibtex download
  • Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C & Holen I (2020) Preventing the progression of breast cancer bone metastasis by CDK inhibition. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 537-538) RIS download Bibtex download
  • Holen I (2020) Highlights of the last year: basic research. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 587-587) RIS download Bibtex download
  • Chen X, Hughes R, Mullin N, Hawkins R, Holen I, Brown N & Hobbs J (2019) Supracellular Mechanical Architecture of the Intact Bone Microenvironment. EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, Vol. 48 (pp S100-S100) RIS download Bibtex download
  • Ottewell PD, Lefley DV, Freeman K, Gregory WM, Hanby AM, Spicer-Hadlington AR, Liu X, Bradbury SM, Hambley L, Allocca G , Cookson V et al (2019) Abstract P1-05-01: Breast cancer cell-derived IL-1B drives metastasis and colonisation of the bone microenvironment. Poster Session Abstracts RIS download Bibtex download
  • Hughes R, Ottewell P, Hobbs J, Holen I & Brown NJ (2019) Breast Cancer Metastasis to Bone: The Role of the Perivascular Niche in Regulating Tumour Cell Dormancy. JOURNAL OF VASCULAR RESEARCH, Vol. 56 (pp 17-18) RIS download Bibtex download
  • Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) Abstract B13: Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence. Early Clinical Opportunities RIS download Bibtex download
  • (2018) 1st UK Interdisciplinary Breast Cancer Symposium—15th–16th January 2018. Breast Cancer Research and Treatment, Vol. 167(1) (pp 309-405) RIS download Bibtex download
  • Lefley D, Nutter F, Brown H, Tulotta C, Eyre R, Clarke R, Alferez D, Wilkinson M, Holen I & Ottewell P (2017) Human specific models for studying ER plus ve and ER- ve breast cancer bone metastasis. CLINICAL & EXPERIMENTAL METASTASIS, Vol. 34(8) (pp 516-516) View this article in WRRO RIS download Bibtex download
  • Haider MT, Holen I, Brown NJ & Hunter K (2015) SHORT-TERM IN VIVO ADMINISTRATION OF CABOZANTINIB INDUCES RAPID MODIFICATION OF THE BONE MARROW VASCULARITY. JOURNAL OF VASCULAR RESEARCH, Vol. 52 (pp 28-28) RIS download Bibtex download
  • Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Marshall H, Banks RE, Selby PJ, Coleman RE & Brown JE (2013) Abstract P2-11-07: Proteins predictive of bone metastasis development in breast cancer patients. Poster Session Abstracts RIS download Bibtex download
  • Byrne M, Ottewell PD, Holen I, Sanderson T & Cross SS (2012) The Use of p63 in Distinguishing In Situ and Invasive Tumour in the PyMT Mouse Model of Breast Cancer. JOURNAL OF PATHOLOGY, Vol. 228 (pp S38-S38) RIS download Bibtex download
  • Kobayashi-Sakamoto M, Isogai E, Hirose K, Okumura K, Holen I & Chiba I (2011) THROMBIN INDUCES OSTEOPROTEGERIN PRODUCTION VIA PHOSPHATIDYLINOSITOL 3-KINASE PATHWAY IN HUMAN MICROVASCULAR ENDOTHELIAL CELLS. INFLAMMATION RESEARCH, Vol. 60 (pp 216-217) RIS download Bibtex download
  • Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) Early intervention with a single dose of doxorubicin followed by zoledronic acid induces sustained inhibition of breast cancer-induced bone disease in a mouse model. BONE, Vol. 48 (pp S255-S255) RIS download Bibtex download
  • Ottewell PD, Whitworth J & Holen I (2011) THE ROLE OF PLAKOGLOBIN IN THE INITIATION OF BREAST CANCER METASTASES. ANNALS OF ONCOLOGY, Vol. 22 (pp 32-32) RIS download Bibtex download
  • Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22 (pp 58-58) RIS download Bibtex download
  • Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29) RIS download Bibtex download
  • Lunj S, Staton CA, Holen I, Ballmer-Hofer K, Reed MW & Brown NJ (2011) Abstract 5131: Escape from breast cancer therapy, are neuropilins the key. Tumor Biology RIS download Bibtex download
  • Ottewell PD, Brown H, Evans CA, Wind NS, Brown NJ, Coleman RE & Holen I (2011) First evidence for anti-tumour effects of doxorubicin and zoledronic acid from an immunocompetent mouse model. BONE, Vol. 48(1) (pp S42-S42) RIS download Bibtex download
  • Wind NS, Brown H, Ottewell PD, Sadej R, Romanska H, Berditchevski F & Holen I (2011) Does differential expression of CD151 affect the ability of beast cancer cells to establish tumours in bone?. BONE, Vol. 48(1) (pp S45-S45) RIS download Bibtex download
  • Brown* HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) Combination vs single agent treatment: The effects of zoledronic acid+/−doxorubicin on breast tumour growth in bone prior to development of osteolytic bone disease. Bone, Vol. 48(1) (pp S41-S41) RIS download Bibtex download
  • Westbrook JA, Peng J, Cairns DA, Ottewell PD, Holen I, Coleman RE, Selby PJ, Banks RE & Brown JE (2011) Towards biomarkers of bone-metastasis using cellular proteomics. BONE, Vol. 48(1) (pp S33-S33) RIS download Bibtex download
  • Brown HK, Ottewell PD, Evans CA & Holen I (2011) Changes in osteoblast and osteoclast number rely on direct contact with breast cancer cells - Evidence from a longitudinal study of bone metastasis. BONE, Vol. 48(1) (pp S40-S41) RIS download Bibtex download
  • Winter MC, Evans A, Holen I & Coleman RE (2011) The addition of zoledronic acid to combination chemotherapy decreases circulating serum levels of vascular endothelial growth factor (VEGF) in early breast cancer. BONE, Vol. 48(1) (pp S30-S31) RIS download Bibtex download
  • Winter MC, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Mori S, Holen I & Coleman RE (2010) Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer. Poster Session Abstracts RIS download Bibtex download
  • Holen I, Ottewell PD & Coleman RE (2010) Abstract P6-14-03: Zoledronic Acid Reduces Breast Tumour Growth When Combined with Chemotherapy — Emerging Evidence of Anti-Tumour Effects Outside Bone. Poster Session Abstracts RIS download Bibtex download
  • Ottewell PD, Lefely DV, Cross SS, Coleman RE & Holen I (2010) Sustained inhibition of tumour growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid. BONE, Vol. 47 (pp S317-S317) RIS download Bibtex download
  • Brown HK, Ottewell PD, Lefely DV, Coleman RE & Holen I (2010) Effects of doxorubicin followed by zoledronic acid on early, medium and late stage breast tumour growth in bone. BONE, Vol. 47 (pp S318-S319) RIS download Bibtex download
  • Winter MC, Evans A, Holen I & Coleman RE (2010) Exploring the anti-angiogenic potential of zoledronic acid in combination with neoadjuvant chemotherapy in invasive breast cancer. BONE, Vol. 47 (pp S310-S310) RIS download Bibtex download
  • Woodward J, Holen I, Lefley D, Ottewell P & Buttle D (2010) Breast cancer-bone marrow stromal cell interactions modify expression of proteolytic enzymes and regulators of bone turnover. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 91(2) (pp A45-A46) RIS download Bibtex download
  • Bundred NJ, Landberg G, Coleman RE, Morris J, Winter MC, Holen I, Cramer A, Renshaw L, Grassby S & Dixon JM (2009) Short-term biological effects of zoledronic acid combined with letrozole in postmenopausal women with estrogen receptor-positive invasive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15) RIS download Bibtex download
  • Winter MC, Cross SS, Ingram CE, Jolley IJ, Holen I, Hatton MQ, Horsman JM & Coleman R (2009) ANZAC: A NEOADJUVANT BIOMARKER STUDY EXPLORING THE ANTI-TUMOUR ACTIVITY OF THE ADDITION OF ZOLEDRONIC ACID TO CHEMOTHERAPY IN BREAST CANCER. ANNALS OF ONCOLOGY, Vol. 20 (pp 55-55) RIS download Bibtex download
  • Ottewell PD, Leftey DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. CANCER RESEARCH, Vol. 69(2) (pp 200S-201S) RIS download Bibtex download
  • Offewell P, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell cycle arrest in sub-cutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. EJC SUPPLEMENTS, Vol. 6(9) (pp 18-18) RIS download Bibtex download
  • Lefley DV, Holen I, Coleman RE & Ottewell PD (2008) Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid. BREAST CANCER RESEARCH, Vol. 10 (pp S40-S40) View this article in WRRO RIS download Bibtex download
  • Ottewell PD, Lefley DV, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. BREAST CANCER RESEARCH, Vol. 10 (pp S40-S41) View this article in WRRO RIS download Bibtex download
  • Ottewett P, Coleman R & Holen I (2008) Mechanisms of apoptosis and cell cycle arrest in intra-tibial breast tumours treated sequentially with doxorubicin followed by zoledronic acid. CANCER TREATMENT REVIEWS, Vol. 34 (pp S62-S62) RIS download Bibtex download
  • Ottewett P, Croucher P & Holen I (2008) Breast cancer cells cause a reduction in osteoblast number - An early event in the development of osteolytic bone lesions. CANCER TREATMENT REVIEWS, Vol. 34 (pp S56-S56) RIS download Bibtex download
  • Brown HK & Holen I (2008) Zoledronic acid modulates chromosome separation in breast cancer cells by inhibition of Cenp-F prenylation. CANCER TREATMENT REVIEWS, Vol. 34 (pp S60-S61) RIS download Bibtex download
  • Woodward J, Lefley D, Cross N, Ottewell PD, Buttle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A97-A97) RIS download Bibtex download
  • Ottewell PD, Deux B, Monkkonen H, Cross SS, Coleman RE, Clezardin P & Holen I (2007) Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39) RIS download Bibtex download
  • Ottewell PD, Deux B, Monkkonen H, Coleman RE, Clezardin P & Holen I (2007) Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1111-1111) RIS download Bibtex download
  • Woodward JKL, Lefley DV, Cross NA, Ottewell PD, Battle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1142-1143) RIS download Bibtex download
  • Van Pozanki C, Otterwell P, Cross S, Hudis C, Coleman RE & Holen I (2007) Osteoprotegerin (OPG) expression in breast tumors and bone metastases. INT J BIOL MARKER, Vol. 22(1) (pp 83-84) RIS download Bibtex download
  • Kuokkanen J, Monkkonen H, Evans A, Holen I, Jauhiainen M, Auriola S & Monkkonen J (2006) The bisphosphonate treatment related ATP analog formation in different cancer cell lines. BONE, Vol. 39(5) (pp S32-S32) RIS download Bibtex download
  • Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of zoledronic acid and doxorubicin in breast cancer models in vivo. CANCER TREATMENT REVIEWS, Vol. 32 (pp S30-S30) RIS download Bibtex download
  • Holen I, Hannon RA, Ellis SP, Coleman RE & Brown JE (2006) Effects of clodronate on serum osteoprotogerin (OPG) in patients with metastatic bone disease. CANCER TREATMENT REVIEWS, Vol. 32 (pp S40-S40) RIS download Bibtex download
  • Holen I, Santini D, Vincenzi B, Tonini G & Hannon RA (2006) Rapid increase in levels of circulating osteoprotegerin (OPG) in patients with tumour-induced bone disease following zoledronic acid administration. BONE, Vol. 38(3) (pp S75-S75) RIS download Bibtex download
  • Michailidou M, Neville-Webbe HL, Evans CA, Brown NJ, Coleman RE & Holen I (2006) Effects of Zoledronic acid and Paclitaxel on endothelial cells in vitro. BONE, Vol. 38(3) (pp S57-S58) RIS download Bibtex download
  • Monkkonen H, Holen I, Evans A, Jauhiainen M, Auriola S & Monkkonen J (2006) Zoledronic acid induced IPP/ApppI accumulation in different cancer cell lines. BONE, Vol. 38(3) (pp S58-S58) RIS download Bibtex download
  • Neville-Webbe HL, Lefley D, Coleman RE & Holen I (2006) Zoledronic acid (ZOL) and letrozole (LET) induce synergistic levels of apoptosis in breast cancer cells. BONE, Vol. 38(3) (pp S58-S59) RIS download Bibtex download
  • Van Poznak C, Ottewell P, Cross S, Hudis C, Coleman RE & Holen I (2006) Osteoprotegerin (OPG) expression in breast tumours and bone metastases. BONE, Vol. 38(3) (pp S31-S32) RIS download Bibtex download
  • Holen I, Patel R, Lefley DV, Webbe HLN, Coleman RE & Woodward JKL (2006) Effects of zoledronic acid on apoptosis in tumour cell lines; repeated low dosing compared to continuous treatment. BONE, Vol. 38(3) (pp S51-S52) RIS download Bibtex download
  • Kuokkanen J, Monkkonen H, Holen I, Evans CA, Kotilainen HK, Auriola S & Monkkonen J (2006) IPP/ApppI production and cellular drug uptake in synergistic action of doxorubicin and zoledronic acid. BONE, Vol. 38(3) (pp S54-S54) RIS download Bibtex download
  • Cross SS, Ottewell P, Swinscoe M, Majeed AW & Holen I (2006) Osteoprotegerin is strongly expressed in the intratumoural endothelial cells of gastrointestinal carcinomas. JOURNAL OF PATHOLOGY, Vol. 208 (pp 9A-9A) RIS download Bibtex download
  • Holen I, Neville-Webbe H & Coleman RE (2006) Benefits of combined treatments using antiresorptive agents and cytotoxic drugs. BREAST CANCER RESEARCH, Vol. 8 (pp S4-S4) View this article in WRRO RIS download Bibtex download
  • Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo. BREAST CANCER RESEARCH, Vol. 8 (pp S17-S17) View this article in WRRO RIS download Bibtex download
  • Michailidou M, Brown N, Coleman RE & Holen I (2006) Effects of combined treatment with Zometa and Taxol on endothelial cells in vitro. BREAST CANCER RESEARCH, Vol. 8 (pp S18-S18) View this article in WRRO RIS download Bibtex download
  • Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and anti-resorptive agents in vitro and in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S290-S290) RIS download Bibtex download
  • Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is expressed in human breast cancers and has a significant negative association with tumours with poor prognosis.. JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27) RIS download Bibtex download
  • Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) There is a general loss of expression of receptor activator of nFkB ligand (RANKL) in human breast cancers but retention of expression has a significant negative association with expression of oestrogen receptor (ER). JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27) RIS download Bibtex download
  • Woodward JKL, Neville-Webbe H, Coleman RE & Holen I (2005) The effects of zoledronic acid and doxorubicin in combination on breast cancer cell invasion in vitro. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(7) (pp 1299-1299) RIS download Bibtex download
  • Cross SS, Yang Z, Woodward JKL, Balasubramanian SP, Reed MWR, Coleman RE, Brown NJ & Holen I (2005) Tumour endothelial cells express osteoprotegerin (OPG) - A potential role in tumour angiogenesis?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S37-S38) RIS download Bibtex download
  • Neville-Webbe HL, Coleman RE & Holen I (2005) Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S41-S41) RIS download Bibtex download
  • Woodward J, Coleman R, Neville-Webbe H & Holen I (2005) The combined effects of zoledronic acid (ZOL) and doxorubicin (DOX) on breast cancer cell invasion in vitro. CANCER TREATMENT REVIEWS, Vol. 31 (pp S43-S43) RIS download Bibtex download
  • Neville-Webbe HL, Coleman RE & Holen I (2005) Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S28-S28) RIS download Bibtex download
  • Evans CA, Neville-Webbe HL, Coleman RE & Holen I (2005) Differential induction of apoptosis following sequential treatments using cytotoxic drugs and zoledronic acid. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S36) RIS download Bibtex download
  • Croucher P, Holen I & Eaton C (2005) Nonosseous effects of osteoprotegerin. CANCER TREATMENT REVIEWS, Vol. 31 (pp S14-S15) RIS download Bibtex download
  • Spencer A, Cross SS, Holen I, Ackroyd R, Stoddard CJ & Bury JP (2004) Expression of osteoprotegerin (OPG) and TRAIL in oesophageal carcinoma and non-neoplastic gastric and oesophageal mucosa. JOURNAL OF PATHOLOGY, Vol. 204 (pp 50A-50A) RIS download Bibtex download
  • Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2004) Zoledronic acid (ZOL) in combination with doxorubicin (DOX) has synergistic effects on apoptosis of breast cancer cells (BCCs) in vitro. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1598-1598) RIS download Bibtex download
  • Cross SS, Balasubramanian SP, Evans CA, Reed MWR & Holen I (2004) Osteoprotegerin is overexpressed in breast cancers and intratumoural endothelial cells and is significantly associated with tumour grade but not with axillary lymph node metastasis. JOURNAL OF PATHOLOGY, Vol. 204 (pp 14A-14A) RIS download Bibtex download
  • Nyambo R, Neville-Webbe H, Holen I, Cross NA, Hamdy FC & Eaton CL (2004) Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1572-1572) RIS download Bibtex download
  • Eaton CL, Wells JM, Holen I, Croucher PI & Hamdy FC (2004) Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1585-1585) RIS download Bibtex download
  • Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2004) Combined treatments of breast cancer cells using bisphosphonates and doxorubicin. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(6) (pp 1035-1035) RIS download Bibtex download
  • Neville-Webbe H, Coleman RE & Holen I (2004) Zoledronic acid and paclitaxel have synergistic antitumor activity and induce apoptotic tumor cell death at clinically relevant concentrations. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S132-S132) RIS download Bibtex download
  • Neville-Webbe HL, Evans A, Coleman RE & Holen I (2004) Sequential exposure of breast cancer cells to cytotoxic agents and zoledronic acid induces synergistic increase in apoptotic cell death.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S72-S72) RIS download Bibtex download
  • Neville-Webbe HL, Evans A, Coleman RE & Holen I (2004) Presence of BRCA1 gene enhances levels of apoptosis induced by combination treatment with doxorubicin (DOX) and zoledronic acid (ZOL).. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S73-S73) RIS download Bibtex download
  • Van Poznac C, Cross SS, Saggese M, Lippitt JM, Hudis C, Coleman RE & Holen I (2004) Human breast cancers express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and receptor activator of nFkB ligand (RANKL). BONE, Vol. 34 (pp S29-S29) RIS download Bibtex download
  • Evans A, Neville-Webbe H, Coleman RE & Holen I (2004) Zoledronic acid and TRAIL induce synergistic increase in apoptotic tumor cell death. BONE, Vol. 34 (pp S56-S56) RIS download Bibtex download
  • Neville-Webbe H, Coleman RE & Holen I (2004) Paclitaxel and zoledronic acid induce synergistic increase in apoptotic tumour cell death at clinically relevant concentrations. BONE, Vol. 34 (pp S67-S68) RIS download Bibtex download
  • Cross SS, Van Poznak C, Hudis C & Holen I (2003) The expression of osteoprotegerin co-localises with columnar cell change in human breast tissue. JOURNAL OF PATHOLOGY, Vol. 201 (pp 32A-32A) RIS download Bibtex download
  • Van Poznak CH, Cross SS, Hudis C, Panageas KS, Coleman RE & Holen I (2003) Osteoprotegerin expression correlates with ER/PR status in human breast tumors.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S310-S310) RIS download Bibtex download
  • Naylor KE, Rogers A, Smith C, Hall V, Fraser RB, Holen I, Lippitt J, Eastell R & Blumsohn A (2003) Source of maternal serum osteoprotegerin during human pregnancy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18(7) (pp 1376-1376) RIS download Bibtex download
  • Neville-Webbe HL, Evans A, Eaton C, Coleman R & Holen I (2003) Bone marrow stromal cell-derived osteoproteger in (OPG) protects breast cancer cells from trail-induced apoptosis. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S25-S25) RIS download Bibtex download
  • Nyambo R, Cross NA, Lippit J, Holen I, Bryden AAG & Eaton CL (2003) Human bone marrow stromal cells (hBMSC) protect prostate cancer cells from trail induced apoptosis. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S26-S26) RIS download Bibtex download
  • Chandrasekharan S, Buttle DJ, Holen I, Cross NA & Hamdy FC (2003) Expression pattern of the ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) proteinases in human prostate cancer celllines. JOURNAL OF UROLOGY, Vol. 169(4) (pp 58-58) RIS download Bibtex download
  • Van Poznak CH, Cross SS, Hudis C, Norton L, Panageas KS, Coleman RE & Holen I (2003) Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) are expressed in human breast tumors.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 82 (pp S162-S162) RIS download Bibtex download
  • Holen I, Wells JM, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Jagdev SP, Hamdy FC & Eaton CL (2002) The role of osteoprotegerin in breast and prostate cancer. J BONE MINER RES, Vol. 17(7) (pp 1339-1339) RIS download Bibtex download
  • Holen I, Croucher PI, Evans AC, Lippitt JM, Hamdy FC, Coleman RE & Eaton CL (2002) OPG is a survival factor for breast- and prostate cancer cells in vitro. BONE, Vol. 30(3) (pp 28S-28S) RIS download Bibtex download
  • Gordon PB, Holen I & Seglen PO (1991) Effects of adrenergic agonists and antagonists on autophagic activity in isolated rat liver cells. Biomedica Biochimica Acta, Vol. 50(4-6) (pp 383-387) RIS download Bibtex download
  • Holen I, Gordon PB & Seglen PO (1991) Role of cyclic nucleotides in the control of hepatic autophagy. Biomedica Biochimica Acta, Vol. 50(4-6) (pp 389-392) RIS download Bibtex download

Website content

Other

Preprints

Research group

PhD students

  • Elisavet Theodoulou
  • Jacky Wong
Professional activities and memberships

I am the Science Lead for the Sheffield Experimental Cancer Medicine Centre as well as a Trustee of Breast Cancer Now, and the NIHR Doctoral Research Fellowship review panel. I am a member of the executive committee that organises the UK Interdisciplinary Breast Cancer Symposium (2018, 2020) that will now be a bi-annual meeting.

I am the incoming Chair of the Executive Committee of British Association for Cancer Research, serve on a number of international expert review panels and committees and journal editorial boards.